Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Leif Bjermer(Lund University), Matthew Germinaro(Johnson & Johnson (United States)), James Zangrilli(Teva Pharmaceuticals (United States)), Jorge Máspero, Catherine Lemière(Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal), Sivan Weiss(Teva Pharmaceuticals (Israel))
Cited by 426
Related Papers
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Overdiagnosis of asthma in obese and nonobese adults
|Canadian Medical Association Journal|2008|409
EUFOREA consensus on biologics for CRSwNP with or without asthma
|Allergy|2019|378
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329